Propensity score adjusted comparison of three-factor versus four-factor prothrombin complex concentrate for emergent warfarin reversal: a retrospective cohort study

Table 4 Regression Models

Factors	OR (95% CI)	P
Univariate Logistic Regression for INR Goal Met
PCC4	14.44 (3.80–54.93)	< 0.001
Female	3.48 (1.36–8.90)	0.009
Age	1.00 (0.98–1.03)	0.85
Weight (kg)	1.00 (0.98–1.02)	0.71
Dose (per 500 unit vial)	1.23 (0.92–1.63)	0.16
Bleed type
Other	Ref.
Intracranial	2.17 (0.70–6.68)	0.18
Gastrointestinal	2.00 (0.45–8.94)	0.36
Initial INR	0.78 (0.61–1.01)	0.06
FFP units used	1.05 (0.67–1.63)	0.84
Time from pre- to post-PCC INR (in hours)	1.28 (1.08–1.53)	0.005
Survivors	1.12 (0.42–3.00)	0.82
Length of stay, all	0.95 (0.88–1.03)	0.22
Length of stay, survivors	0.94 (0.85–1.05)	0.27
Thromboembolism, yes	0.43 (0.10–1.79)	0.25
PS Adjusted Logistic Regression	AOR (95% CI)
PCC4	10.55 (2.17–51.24)	< 0.001
Linear Regression	Coefficient (95% CI)
Intercept (mean INR change PCC3)	1.64 (1.22–2.07)	< 0.001
mean INR change PCC4	0.91 (0.12–1.70)	0.03
Intercept (post-PCC INR PCC3)	1.90 (1.69–2.12)	< 0.001
post-PCC INR PCC4	−0.51 (−0.91- -0.12)	0.01
PS Adjusted Linear Regression	Coefficient (95% CI)
Intercept (mean INR change PCC3)	1.39 (0.89–1.89)	< 0.001
mean INR change PCC4	0.30 (−0.74–1.33)	0.56
Intercept (post-PCC INR PCC3)	1.98 (1.73–2.23)	< 0.001
post-PCC INR PCC4	−0.45 (− 0.85- -0.19)	0.21

AOR adjusted odds ratio, CI confidence interval, INR international normalized ratio, FFP fresh frozen plasma, NA not applicable, OR odds ratio, PCC prothrombin complex concentrate, PCC3 3-factor PCC, PCC4 4-factor PCC, PS propensity score, Ref. reference group

ISSN: 1471-227X